Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations
The predictive value of PLR was more apparent in patients treated with 1st or 2nd generation TKIs compared to those treated with osimertinib. Third generation EGFR TKIs may be more efficacious in treating patients with laboratory findings previously shown to predict poor survival. The significant changes in peripheral cell counts suggest variable tumor microenvironment changes dependent on the generation of TKI received.
Authors
- Jacob Thomas (ORCID: https://orcid.org/0000-0002-8420-366X)
- Robert C. Hsu (ORCID: https://orcid.org/0000-0003-3957-6106)
- Jorge J. Nieva (ORCID: https://orcid.org/0000-0003-1605-4719)
- Dhruv Ramaswami (ORCID: https://orcid.org/0000-0002-9798-2877)
- Ryan Cooper (ORCID: https://orcid.org/0000-0002-5473-2392)
Institutions
- University of Southern California (US)
- LAC+USC Medical Center (US)
- USC Norris Comprehensive Cancer Center (US)
Publication Details
- Journal
- Discover Oncology
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1007/s12672-024-01606-9
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- USC Norris Comprehensive Cancer Center